Please assess the completion status of the following clinical trial:

Trial Title: PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Victim of a traumatic event leading to personal injury~* Patient experienced a feeling of intense fear, hopelessness, or horror during the course of the event or immediately afterward~* Positive screen on the ASDS (for inclusion in the randomization phase); a total ASDS score of ≥ 37 (including a dissociative score of ≥ 9) will be counted as a positive screen.~Exclusion Criteria:~* Age \< 18~* Pregnant women, lactating women, or women not using acceptable form of birth control~* Epilepsy or head trauma resulting in seizures~* Current or historical schizophrenia, bipolar disorder, mental retardation, OCD, eating disorders, dementia, delirium, or self-injurious behavior~* Current/previously diagnosed PTSD~* History of hypersensitivity to sertraline~* Trauma occurring \> 7 days prior to likely first treatment in the randomization phase of the trial.~* Unable to provide informed consent for participation in the study protocol.~* Patient at high risk of recurrent bleeding despite surgical stabilization~* Patient with a history of serotonin syndrome~* Patient non-fluent in English~* Patient currently prescribed an antidepressant (any SSRI, SNRI, TCA, MAOI, mirtazapine, or trazodone in excess of 100mg per day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sertraline (Type: EXPERIMENTAL): Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age \>65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.

Based on this trial design, predict the completion outcome and termination type (if applicable).